Brokerages Set GSK plc (NYSE:GSK) Target Price at $47.00

Shares of GSK plc (NYSE:GSKGet Free Report) have earned an average rating of “Hold” from the six brokerages that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $47.00.

Several research firms have issued reports on GSK. The Goldman Sachs Group began coverage on GSK in a research note on Thursday. They issued a “neutral” rating and a $47.00 target price on the stock. Citigroup raised GSK from a “neutral” rating to a “buy” rating in a report on Tuesday, February 13th. Finally, Guggenheim raised GSK from a “neutral” rating to a “buy” rating in a report on Monday, March 4th.

View Our Latest Stock Report on GSK

Institutional Investors Weigh In On GSK

A number of institutional investors and hedge funds have recently modified their holdings of the company. 1832 Asset Management L.P. lifted its holdings in shares of GSK by 9.1% during the first quarter. 1832 Asset Management L.P. now owns 3,078 shares of the pharmaceutical company’s stock worth $132,000 after purchasing an additional 257 shares during the period. Personal CFO Solutions LLC lifted its holdings in GSK by 2.7% in the fourth quarter. Personal CFO Solutions LLC now owns 10,087 shares of the pharmaceutical company’s stock valued at $374,000 after acquiring an additional 263 shares during the period. J.W. Cole Advisors Inc. lifted its holdings in GSK by 4.7% in the first quarter. J.W. Cole Advisors Inc. now owns 6,097 shares of the pharmaceutical company’s stock valued at $261,000 after acquiring an additional 271 shares during the period. Chapin Davis Inc. lifted its holdings in GSK by 2.2% in the first quarter. Chapin Davis Inc. now owns 14,231 shares of the pharmaceutical company’s stock valued at $610,000 after acquiring an additional 300 shares during the period. Finally, Dorsey & Whitney Trust CO LLC lifted its holdings in GSK by 2.9% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 10,986 shares of the pharmaceutical company’s stock valued at $407,000 after acquiring an additional 306 shares during the period. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Stock Performance

GSK stock opened at $44.77 on Monday. The firm has a market cap of $92.78 billion, a price-to-earnings ratio of 16.22, a PEG ratio of 1.34 and a beta of 0.65. The company has a quick ratio of 0.58, a current ratio of 0.87 and a debt-to-equity ratio of 1.15. GSK has a twelve month low of $33.33 and a twelve month high of $45.92. The business’s fifty day simple moving average is $42.76 and its two-hundred day simple moving average is $40.47.

GSK (NYSE:GSKGet Free Report) last announced its quarterly earnings results on Wednesday, May 1st. The pharmaceutical company reported $1.09 EPS for the quarter, beating the consensus estimate of $0.94 by $0.15. The firm had revenue of $9.34 billion for the quarter, compared to analyst estimates of $8.98 billion. GSK had a return on equity of 51.54% and a net margin of 14.62%. Analysts predict that GSK will post 4.11 earnings per share for the current year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 11th. Investors of record on Friday, May 17th will be issued a dividend of $0.3762 per share. This is an increase from GSK’s previous quarterly dividend of $0.36. The ex-dividend date is Thursday, May 16th. This represents a $1.50 dividend on an annualized basis and a dividend yield of 3.36%. GSK’s payout ratio is 53.26%.

GSK Company Profile

(Get Free Report

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

See Also

Analyst Recommendations for GSK (NYSE:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.